Clinical Trial

A Study to Evaluate Safety and Efficacy of BEY1107 in Combination with Capecitabine in Patients with Metastatic Colorectal Cancer

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This is a Phase 1/2 study to evaluate the maximum tolerated dose, safety and efficacy of BEY1107 in combination with capecitabine in patients with metastatic colorectal cancer refractory or intolerant to standard of care (SoC).
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2021-10-25.
Trial Details
NCT Number NCT05093907
Lead Sponsor BeyondBio Inc.
Conditions Metastatic Colorectal Cancer
Enrollment 27 participants
Start Date 2021-08-31
Primary Completion 2026-11-30 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-03-10